Trial Profile
Phase IIa Study of Nimotuzumab Plus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer With Wild Type K-ras.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- 11 Sep 2009 New trial record